Key facts
- Notable investors include Tech Incubator Program for Startup, IBK Changgong, Shinhan Capital, HG Initiative, Intops Investment — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for AIVIS
- ·The full record, as it builds
Funding rounds
No funding rounds for AIVIS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AIVIS
Developer of a medical artificial intelligence technology designed for analyzing tissue slides in the human body. The company's technology uses modern technology for fundamental biopsy assessment and eliminates the need for immunohistochemistry staining, enabling pathologists to predict breast cancer treatment and prognosis by deriving medical information unseen by the human eye.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2021
- Employees
- 41
- Website
- aivis.kr/
- Ownership
- Privately Held (backing)
AIVIS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AIVIS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AIVIS in its N-PORT filings yet. We sweep new filings monthly.